Recombinant Human Interleukin-11 (rhIL-11)

DRUG2 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, The First Affiliated Hospital with Nanjing Medical University

Conditions

CTIT: Cancer Therapy Induced ThrombocytopeniaCrohn DiseaseInflammatory Bowel Disease

Phase 2

Study Evaluating rhIL-11 in Active Crohn's Disease

CompletedNCT00040521

Wyeth is now a wholly owned subsidiary of PfizerCrohn Disease, Inflammatory Bowel Disease

Start: 2002-04-30End: 2003-10-31Updated: 2013-02-08

Phase 3

FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

Not yet recruitingNCT06759636

The First Affiliated Hospital with Nanjing Medical UniversityCTIT: Cancer Therapy Induced Thrombocytopenia

Start: 2025-01-21End: 2026-07-21Target: 88Updated: 2025-01-06